REG - ValiRx PLC - Conclusion of Evaluation with Stingray

ValiRxAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260602:nRSB5300Ga&default-theme=true

RNS Number : 5300G  ValiRx PLC  02 June 2026

2 June 2026

 

ValiRx PLC

("ValiRx" or the "Company")

 

Conclusion of Evaluation with Stingray

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health provides the following
update at the conclusion of the Evaluation Agreement with Stingray Bio Limited
("Stingray") announced on 5 August 2025.

Under the terms of the Evaluation Agreement with Stingray, ValiRx carried out
in-silico lead optimisation of potency and target selectivity. Despite some
interesting in-silico results, it was concluded the technology had not met the
strict criteria for the Company to exercise its option to license the
technology on pre-agreed terms.

 

Under the terms of the Evaluation Agreement, the jointly owned results will
return to Stingray and, if Stingray secures alternative investment within 12
months of the Evaluation Agreement's completion, ValiRx will be entitled to a
cash payment of 1.5x its total investment (estimated at approximately
£50,000, including outsourced work and internal resources).

Mark Eccleston, CEO of ValiRx commented "We have completed this second
evaluation phase of the Stingray assets ahead of schedule and well within
budget. This phase focussed on in-silico lead optimisation following the
initial evaluations of lead assets by Inaphaea and would require significant
further lead optimisation and development to get to the candidate stage so we
have elected not to proceed as we focus our resources on later stage assets.

 

This was the first of our new style, hybrid approach to evaluation and
development programmes and so, whilst we are not progressing with the asset
ourselves, the evaluation results will be assigned back to Stingray and we
will retain some upside if it is commercialised in the next 12 months."

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement

 We encourage all investors to share questions     https://valirx.com/link/egGpbe (https://valirx.com/link/egGpbe)

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 646 5491

                                                   www.vformation..co.uk

 Jocelyn Braithwaite

                                                   jocelyn@vformation.co.uk

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUQWQUPQGAG



            Copyright 2019 Regulatory News Service, all rights reserved